New Jersey has the highest rate of HIV due to injection drug use (IDU).<br />Approximately 40% of the 71,812 individuals identified as being infected with HIV are IDUs.<br />Hepatitis and HIV remain prevalent in IDUs.<br />Blinded studies in drug treatment programs indicate infection rates of 50% - 90% in injection heroin users.<br />Why Exchange Syringes?<br />
Harm Reduction seeks to minimize the harm caused by injection drug use.<br />It is based on the principle “one new syringe for each injection.”<br />It attempts to reach people “where they’re at.”<br />Principles of Harm Reduction <br />
Precontemplation (Not yet acknowledging that there is a problem behavior that needs to be changed) <br />Contemplation (Acknowledging that there is a problem but not yet ready or sure of wanting to make a change) <br />Preparation/Determination (Getting ready to change) <br />Stages of Change<br />
Action/Willpower (Changing behavior)<br />Maintenance (Maintaining the behavior change) and <br />Relapse (Returning to older behaviors and abandoning the new changes) <br />Stages of Change (Cont…)<br />
In 2007 New Jersey became the last state to liberalize access to syringes without a prescription.<br />Syringe Exchange Programs (SEPs) are totally anonymous, no identifying information is collected.<br />SEPs are pilot programs and only allowed in six cities.<br />History of NJCRI’s Project Access<br />
In 2007 the City of Newark applied to the state to open a Syringe Exchange Program.<br />NJCRI secured private funding and received permission from the City of Newark to open NJCRI’s Project Access.<br />Project Access opens on February 19, 2008.<br />Initial goal was to enroll 175 clients.<br />History of NJCRI’s Project Access (Cont…)<br />
Present enrollement is approximately 1,300 clients. <br />Funding has been secured from six foundations including:<br />Comer Foundation<br />Diamond Fund<br />Health Care Foundation<br />NJ AIDS Partnership<br />M.A.C. AIDS Foundation<br />Tides Foundation<br />History of NJCRI’s Project Access (Cont…)<br />
Presently budgeted at $120K per year.<br />No local, state, or federal money is provided to NJCRI’s Project Access.<br />Some funding was one-time only or start-up. Future foundation funding remains uncertain.<br />History of NJCRI’s Project Access (Cont…)<br />
Average client age is 40. <br />Majority of clients are African/American.<br />Sixty percent are male.<br />Most clients are from Newark, Irvington, East Orange, etc.<br />Results<br />
Significant numbers of suburban youth are accessing the program.<br />Approximately 30% of NJCRI’s Project Access clients request and are referred to drug treatment.<br />Results (Cont…)<br />
Restrictions on the use of Federal money to support Syringe Exchanges have been lifted. However, at present the Federal government is not funding SEP activities. <br />State money maybe provided in the future.<br />An evaluation report has been sent to the governor recomending funding and removal of the pilot designation for SEPs.<br />Future of NJCRI’s Project Access<br />
Reputable studies indicate that SEPs lessen the risk of infection with hepatitis and/or HIV.<br />These same studies show no increase in injection drug use in localities with SEPs.<br />SEPs serve as gateways to drug treatment, HIV counseling and testing, social services and medical services.<br />Summary<br />
SEPs are cost effective. Syringes cost approximately 0.08 cents each. <br />Treating a single AIDS patient with hugely expensive drugs, and occasional hospitalization, now costs between $300,000 and $600,000 on average, according to the latest studies (Star-Ledger 11/12/09). Therefore, if Project Access prevents one case of HIV per year, it pays for itself many times over.<br />Summary (Cont…)<br />
Bob Baxter, Director<br />NJCRI<br />393 Central Avenue<br />Newark, NJ 07103<br />(973) 483-3444 x 132<br />firstname.lastname@example.org<br />THANK YOU!<br />Contact Information<br />
A particular slide catching your eye?
Clipping is a handy way to collect important slides you want to go back to later.